palovarotene造句

• Palovarotene began phase 2 clinical trials for human testing in October 2016.
• Palovarotene is a drug shown to prevent heterotopic bone formation in animal models of FOP.
• Palovarotene is a retinoic acid receptor gamma ( RAR? ) agonist licensed to Clementia Pharmaceuticals from Roche Pharmaceuticals.
• Palovarotene is currently being investigated as a potential therapy for FOP, a disorder of heterotopic ossification, in humans.
• At Roche, palovarotene was evaluated in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease ( COPD ).
• A 2016 study demonstrated that palovarotene also inhibited spontaneous heterotopic ossification, maintained limb mobility and functioning, and restored skeletal growth in FOP mouse models.
• Clementia licensed palovarotene from Roche Pharmaceuticals, which previously evaluated the compound in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease.
• July 2014 was a milestone in the history of IFOPA-the first clinical trial of a drug to treat FOP . A Phase II clinical trial investigating palovarotene for the treatment of FOP began.
• Palovarotene received Fast Track designation from the U . S . Food and Drug Administration ( FDA ) and orphan designations for the treatment of FOP from both the FDA and the European Medicines Agency ( EMA ).
• Palovarotene is being developed by Clementia Pharmaceuticals and was granted Fast Track and orphan drug designations by the United States Food and Drug Administration for the treatment of FOP and Orphan Medicinal Product Designation by the European Medicines Agency ( EMA ) in 2014.
• In 2011, animal studies demonstrated that RAR? agonists, including palovarotene, blocked new bone formation in both an injury-induced mouse model of heterotopic ossification ( HO ) and a genetically modified biological mouse model of FOP containing a continuously active ACVR1 / ALK2 receptor in a dose-dependent manner.
• Palovarotene is a highly selective retinoic acid receptor gamma ( RAR-? ) agonist that is under investigation as a potential treatment for fibrodysplasia ossificans progressiva ( FOP ), an ultra-rare and severely disabling genetic disease characterized by extra-skeletal bone formation ( heterotopic ossification or HO ) in muscle and soft tissues.
• In August 2015, Clementia Pharmaceuticals also began the enrollment of children ( ages 6 and above ) into its Phase II clinical trial investigating palovarotene for the treatment of FOP . Preclinical studies demonstrated that palovarotene, a retinoic acid receptor gamma agonist, blocked abnormal bone formation in animal models via inhibition of secondary messenger systems in the BMP pathway.
• In August 2015, Clementia Pharmaceuticals also began the enrollment of children ( ages 6 and above ) into its Phase II clinical trial investigating palovarotene for the treatment of FOP . Preclinical studies demonstrated that palovarotene, a retinoic acid receptor gamma agonist, blocked abnormal bone formation in animal models via inhibition of secondary messenger systems in the BMP pathway.